Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.54 |
| ▸ | KIT | P10721 | 9/20 | 0.54 |
| ▸ | ABL2 | P42684 | 4/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | BCR | P11274 | 6/20 | 0.49 |
| ▸ | LYN | P07948 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | ARAF | P10398 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | CSK | P41240 | 1/20 | 0.48 |
| ▸ | FRK | P42685 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251068 | 1.00 | ABL1 (0.54) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL24250903 | 0.98 | ABL1 (0.54) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL29552063 | 0.98 | ABL1 (0.54) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL29551536 | 0.92 | ABL1 (0.58) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL24251075 | 0.92 | ABL1 (0.58) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL24251045 | 0.91 | KIT (0.62) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL29551540 | 0.90 | ABL1 (0.56) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL24250909 | 0.90 | ABL1 (0.56) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL24250902 | 0.89 | KIT (0.61) | ABL1KITABL2PDGFRAKDR | |
| SCHEMBL29551527 | 0.89 | KIT (0.61) | ABL1KITABL2PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885KIT 2333/4885ABL2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.